The heterogeneity of type 1 diabetes: From immunopathology to immune intervention
Authors:
- Marco InfanteMarco Infante
- Rodolfo AlejandroRARodolfo Alejandro
- Andrea FabbriAFAndrea Fabbri
- Camillo RicordiCRCamillo Ricordi
- 1 May 2022
- book chapter
- Published by Elsevier
- p. 83-104
Abstract
No abstract availableKeywords
This publication has 132 references indexed in Scilit:
- Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitusPediatric Diabetes, 2013
- Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeoverJournal of Clinical Investigation, 2012
- Genetics of the HLA Region in the Prediction of Type 1 DiabetesCurrent Diabetes Reports, 2011
- Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyDiabetes, Obesity and Metabolism, 2011
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Insulin Reciprocally Regulates Glucagon Secretion in HumansDiabetes, 2010
- Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist StudyDiabetes, 2010
- The pancreas in human type 1 diabetesSeminars in Immunopathology, 2010
- Type I Diabetes MellitusNew England Journal of Medicine, 1986